Health Care & Life Sciences » Pharmaceuticals | Nabriva Therapeutics AG

Nabriva Therapeutics AG

Nabriva Therapeutics AG ADR
Stock Exchange NASDAQ Stock Market
EPS
$2.1
Market Cap
$176.86 M
Shares Outstanding
72.78 M
Public Float
45.37 M

Profile

Address
Leberstrasse 20
Vienna Wien (Vienna) 1110
Austria
Employees -
Website http://www.nabriva.com
Updated 07/08/2019
Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic available for systemic administration in humans. It develops intravenous and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia and intends to develop lefamulin for additional indications other than pneumonia.

Financials

View All
Created with Highcharts 5.0.14Nabriva Therapeutics AG ADRNet Income. Fiscal year is January-December. All values USD Thousands.11 21011 21013 38013 38046 71146 71154 73054 7302013201420152016010k20k30k40k50k60k
Created with Highcharts 5.0.14Nabriva Therapeutics AG ADRSales/Revenue. Fiscal year is January-December. All values USD Thousands.00003 7463 7466 4636 463201320142015201602k4k6k8k

Carrie L. Bourdow
Director
Thomas Lembck
Chief Information Officer